8 results on '"Smeland, Sigbjørn"'
Search Results
2. Long-term satisfaction with curative treatment and follow-up in prostate cancer survivors.
- Author
-
Monsen, Kari V., Fosså, Sophie D., Myklebust, Tor Å., Smeland, Sigbjørn, Dahl, Alv A., and Stensvold, Andreas
- Subjects
CANCER patient psychology ,THERAPEUTICS ,PATIENT aftercare ,KEY performance indicators (Management) ,SCIENTIFIC observation ,RADICAL prostatectomy ,ATTITUDE (Psychology) ,AGE distribution ,CROSS-sectional method ,PATIENT satisfaction ,PATIENTS' attitudes ,PRIMARY health care ,SEVERITY of illness index ,QUESTIONNAIRES ,CLINICAL medicine ,DESCRIPTIVE statistics ,INTERPROFESSIONAL relations ,LOGISTIC regression analysis ,PROSTATE tumors - Abstract
In a cross-sectional observational study to explore long-term satisfaction with treatment among men who had undergone radical prostatectomy (RP) or definitive pelvic radiotherapy (RT) for prostate cancer (PCa). After mean 7 years from therapy (range: 6–8), 431 PCa-survivors (RP: n = 313, RT: n = 118) completed a mailed questionnaire assessing persistent treatment-related adverse effects (AEs) (Expanded Prostate cancer Index Composite [EPIC-26]) and seven Quality indicators describing satisfaction with the health care service following a most often general practitioner (GP)-led follow-up plan. A logistic regression model evaluated the associations between long-term satisfaction and treatment modality, age, the seven satisfaction-related Quality indicators, and persistent AEs. The significance level was set at p<.05. Four of five (81%) PCa-survivors reported long-term satisfaction with their treatment. In a multivariable model, satisfaction was positively associated with sufficient information about treatment and AEs, patient-perceived sufficient cooperation between the hospital and the GP and sufficient follow-up of AEs (ref.: insufficient). Age ≥70 years (ref.: <70) and a rising summary score within the EPIC-26 sexual domain additionally increased long-term satisfaction. The treatment modality itself (RP versus RT) did not significantly impact on satisfaction. The majority of curatively treated PCa-survivors are satisfied with their treatment more than 5 years after primary therapy. Sufficient information, improved cooperation between the hospital specialists and the responsible GP and optimized follow-up of AEs may further increase long-term satisfaction among prostatectomized and irradiated PCa-survivors. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. Prostatectomy with or without post-operative radiotherapy: long-term adverse effects and quality of life.
- Author
-
Vatne Monsen, Kari, Fosså, Sophie D., Dahl, Alv A., Myklebust, Tor Å., Smeland, Sigbjørn, and Stensvold, Andreas
- Subjects
QUALITY of life ,ANDROGEN deprivation therapy ,PROSTATECTOMY ,RADIOTHERAPY ,URINARY incontinence - Abstract
Few longitudinal studies have compared patient-reported long-term adverse effects after radical prostatectomy (RP) alone and RP followed by radiotherapy (RAD), also analyzing the effect of the development of post-treatment dysfunctions/problems (Symptom Burden) on Health-Related Quality of Life (HRQoL). After median seven years since RP and six years since post-RP RAD, development of EPIC-26 Domain Summary Scores (DSS Changes) and HRQoL scores (SF-12) since the pre-RP situation were evaluated in respectively 317 prostatectomized men without and in 63 patients with additional post-RP RAD. Post-treatment inter-group differences of the prevalent Symptom Burden and of the DSS Changes were calculated. Multivariable logistic regressions evaluated the associations between DSS Changes and post-treatment impaired HRQoL. Compared to RP alone, post-RP RAD increased the post-treatment Symptom Burden, with least inter-group differences within the urinary irritative/obstructive and bowel domain. No significant inter-group difference emerged for the proportions of men with impaired HRQoL. The odds of impaired HRQoL increased significantly with rising DSS Changes (worsening) within the vitality/hormonal domain. Worsening within urinary incontinence and bowel domains significantly increased the odds of impaired physical QoL. High HRQoL scores before RP reduced the odds of post-treatment impaired HRQoL. Living without a partner and use of androgen deprivation therapy increased this odds. Post-RP radiotherapy increases post-treatment Symptom Burden with negative, though limited impact on the patient's HRQoL. Counceling before post-RP radiotherapy should cover this possible development, taking into account the patient's social situation. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Results of the Scandinavian Sarcoma Group XIV protocol for classical osteosarcoma
- Author
-
Smeland, Sigbjørn, primary, Bruland, Øyvind S, additional, Hjorth, Lars, additional, Brosjö, Otte, additional, Bjerkehagen, Bodil, additional, Österlundh, Gustaf, additional, Jakobson, Åke, additional, Hall, Kirsten Sundby, additional, Monge, Odd R, additional, Björk, Olle, additional, and Alvegaard, Thor A, additional
- Published
- 2011
- Full Text
- View/download PDF
5. Radiation-induced sarcoma: 25-year experience from The Norwegian Radium Hospital.
- Author
-
Bjerkehagen, Bodil, Smeland, Sigbjørn, Walberg, Lise, Skjeldal, Sigmund, Sundby Hall, Kirsten, Nesland, Jahn M., Cvancarova Småstuen, Milada, Fosså, Sophie D., and Sæter, Gunnar
- Subjects
- *
SARCOMA , *RADIOTHERAPY complications , *DISEASE prevalence , *RADIATION , *HEALTH outcome assessment - Abstract
Background. The aim of this study was to determine the prevalence and outcome of radiation-induced sarcomas (RISs) among sarcoma patients referred to the Norwegian Radium Hospital (NRH). Material and Methods. Ninety patients were identified from the institutional sarcoma data base. Medical records and histological and cytological material from both primary and secondary tumours were reviewed. Results. RIS represented 3.0 % of the sarcomas in the data base. The median latency time from radiotherapy of the primary tumour to the diagnosis of RIS was 13.6 years (range 2.5-57.8 years). Gynaecological, breast and testicular cancers were the most common primary diagnoses. For the RISs 13 different histological types were identified including 25 malignant fibrous histiocytomas (28% of all) and 22 osteosarcomas (24%). The sarcoma-related 5-year crude survival was 33% (95 % CI 23-43 %). Unfavourable prognostic factors were metastases at presentation, incomplete surgery and presence of tumour necrosis. Conclusion. Radiation-induced sarcoma is rare and harbours an aggressive clinical behaviour. Complete surgical resection is mandatory for cure. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
6. Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series.
- Author
-
Müller, Christoph R., Smeland, Sigbjørn, Bauer, Henrik C. F., Sæter, Gunnar, and Strander, Hans
- Subjects
- *
INTERFERONS , *OSTEOSARCOMA , *CANCER chemotherapy , *CANCER patients , *LEUCOCYTES , *CANCER treatment , *CLINICAL trials - Abstract
This experience of single agent interferon-α treatment in high-grade osteosarcoma was based on observed anti-osteosarcoma activity in laboratory models and was started before introduction of aggressive combination chemotherapy. From 1971 to 1990, 89 consecutive patients with non-metastatic high-grade osteosarcoma received semi-purified, leukocyte interferon-α as adjuvant treatment. From 1971 to 1984, 70 patients were given a dose of 3 MIU daily for one month followed by 3 times weekly for an additional 17 months. For 19 patients treated from 1985 to 1990 the dose was increased to 3 MIU daily and the treatment duration extended to 3–5 years. All patients underwent surgery prior to interferon treatment. The toxicity was mainly constitutional and long-term toxicity was virtually absent. With a median follow-up of 12 years the observed 10-year metastases-free and sarcoma specific survival rates were 39% and 43%, respectively. Only one of seven survivors after relapse received chemotherapy. This work suggests activity of interferon-α as adjuvant treatment in high-grade osteosarcoma. The efficacy of interferon in combination with standard therapy should be explored in randomized trials. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
7. Acta Oncologica Nordic Precision Cancer Medicine Symposium 2023 - merging clinical research and standard healthcare.
- Author
-
Bjørgo E, Fagereng GL, Russnes HG, Smeland S, Taskén K, and Helland Å
- Subjects
- Humans, Biomedical Research, Scandinavian and Nordic Countries, Delivery of Health Care standards, Congresses as Topic, Precision Medicine methods, Neoplasms therapy, Neoplasms drug therapy, Medical Oncology methods
- Published
- 2024
- Full Text
- View/download PDF
8. IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
- Author
-
Puco K, Fagereng GL, Brabrand S, Niehusmann P, Støre Blix E, Samdal Steinskog ES, Haug Å, Fredvik Torkildsen C, Oppedal IA, Meltzer S, Flobak Å, Johansson KAM, Bjørge L, Hjortland GO, Dalhaug A, Lund JÅ, Gilje B, Grønlie Cameron M, Hovland R, Falk RS, Smeland S, Giercksky Russnes HE, Taskén K, and Helland Å
- Subjects
- Humans, Norway, Prospective Studies, Male, Female, Middle Aged, Aged, High-Throughput Nucleotide Sequencing, Molecular Targeted Therapy methods, Adult, Patient Selection, Precision Medicine methods, Neoplasms genetics, Neoplasms therapy, Neoplasms drug therapy
- Abstract
Background and Purpose: In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if targeted treatments are matched with actionable genomic alterations. In the IMPRESS-Norway trial (NCT04817956), patients are treated with drugs outside the labelled indication based on their tumours molecular profile., Patients and Methods: IMPRESS-Norway is a national, prospective, non-randomised, precision cancer medicine trial, offering treatment to patients with advanced-stage disease, progressing on standard treatment. Comprehensive next-generation sequencing, TruSight Oncology 500, is used for screening. Patients with tumours harbouring molecular alterations with matched targeted therapies available in IMPRESS-Norway, are offered treatment. Currently, 24 drugs are available in the study. Primary study endpoints are percentage of patients offered treatment in the trial, and disease control rate (DCR) defined as complete or partial response or stable disease in evaluable patients at 16 weeks (W16) of treatment. Secondary endpoint presented is DCR in all treated patients., Results: Between April 2021 and October 2023, 1,167 patients were screened, and an actionable mutation with matching drug was identified for 358 patients. By the data cut off 186 patients have initiated treatment, 170 had a minimum follow-up time of 16 weeks, and 145 also had evaluable disease. In patients with evaluable disease, the DCR was 40% (58/145). Secondary endpoint analysis of DCR in all treated patients, showed DCR of 34% (58/170)., Interpretation: Precision cancer medicine demonstrates encouraging clinical effect in a subset of patients included in the IMPRESS-Norway trial.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.